Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07425717
Starting soon Not applicable

Multicenter Study of Transcranial Magnetic Stimulation on Vision Restoration

NCT07425717 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai High Myopia Study Group
Phase
Not applicable
Started
2026-06-01
Last updated
2026-02-23

Condition(s) studied

Retinal DegenerationVision Impairment and Blindness

Investigational drug(s) / intervention(s)

Transcranial magnetic stimulation targeting occipital visual cortexSham stimulation

Transcranial magnetic stimulation targeting occipital visual cortex: Transcranial magnetic stimulation targeting occipital visual cortex

Sham stimulation: identical procedure using a sham coil without effective magnetic field output

Study summary

The goal of this clinical trial is to learn if transcranial magnetic stimulation (TMS) works to restore vision in adults with severe retinal degeneration. It will also learn about the safety of TMS treatment. The main questions it aims to answer are:

1. Does TMS treatment improve the visual function of participants?
2. What medical problems do participants have when receiving TMS treatment? Researchers will compare TMS treatment to a sham stimulation (identical procedures using a sham coil without effective magnetic field output) to see if TMS treatment works to restore their vision.

Participants will:

UndergoTMS treatment to a sham stimulation for consecutive 5 days Visit the clinic at 5 days, 4 weeks, 3 months, 6 months, 12 months after start of the treatment for checkups and tests

Eligibility

Sex
ALL
Min age
45 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * between 45 and 70 years old * bilateral severe MMD (META-PM grades ≥ 3) * no prior TMS history or contraindications to TMS Exclusion Criteria: * other significant ocular diseases, such as refractive media opacity, glaucoma, uveitis, ocular trauma, untreated retinal detachment, or lens dislocation * received anti-vascular endothelial growth factor treatment or other ocular surgeries within 3 months * history of epilepsy or family history of epilepsy, intracranial metal implants, or severe cerebrovascular diseases * mental illness, cognitive impairment (MMSE score \< 24), unable to communicate effectively * severe heart disease, liver or kidney dysfunction, or coagulation disorders * pregnant or lactating women * currently participating in other clinical trials.

Primary outcome measure(s)

  • Best-corrected visual acuity (BCVA) change — Baseline and 3 months
    the change of best-corrected visual acuity (BCVA, measured by internationally standard EDTRS chart) between 3 months after the end of treatment and baseline

Trial sites (4)

FacilityCityRegionStatus
Hong Kong Polytechnic University Hong Kong China
Eye and Ear, Nose, Throat Hospital of Fudan University Shanghai China
Huadong Hospital of Fudan University Shanghai China
Shanghai Ninth People's Hospital Shanghai China

More Shanghai High Myopia Study Group trials in China

Artificial Intelligence for Highly Myopic Cataract Recruiting
Shanghai High Myopia Study Recruiting

Other trials for the same condition

Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis Active, not recruiting
Minocycline for Chronic Autoimmune Uveitis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07425717 on ClinicalTrials.gov ↗ ← All trials in China